SKIN · Beauty Health Co - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $64.91M | - | $70.66M | $78.19M | $69.58M | - | $78.80M | $90.59M | $81.40M | - |
| Cost of Revenue | $20.47M | - | $25.02M | $29.07M | $21.00M | - | $38.15M | $49.65M | $33.04M | - |
| Gross Profit | $44.44M | - | $45.63M | $49.11M | $48.58M | - | $40.65M | $40.94M | $48.36M | - |
| R&D | $1.10M | - | $1.70M | $1.25M | $998.0K | - | $1.11M | $1.16M | $2.81M | - |
| SG&A | $21.94M | - | $29.25M | $27.45M | $33.56M | - | $33.44M | $31.41M | $28.86M | - |
| Total Operating Expenses | $46.24M | - | $51.88M | $51.81M | $60.60M | - | $62.16M | $63.05M | $65.35M | - |
| D&A | $563.0K | - | - | - | $1.86M | - | - | - | $2.77M | - |
| Operating Income | ($1.80M) | - | ($6.24M) | ($2.70M) | ($12.02M) | - | ($21.52M) | ($22.11M) | ($16.99M) | - |
| Interest Expense | $6.35M | - | $6.31M | $4.14M | $3.03M | - | $3.44M | $2.45M | $3.03M | - |
| Income Tax | ($184.0K) | - | $386.0K | ($993.0K) | $892.0K | - | $1.95M | ($353.0K) | ($659.0K) | - |
| Net Income | ($6.63M) | - | ($11.03M) | $19.71M | ($10.10M) | - | ($18.29M) | $202.0K | ($679.0K) | - |
| EPS - Basic | ($0.05) | - | ($0.09) | $0.16 | ($0.08) | - | ($0.15) | $0.00 | ($0.01) | - |
| EPS - Diluted | ($0.05) | - | ($0.09) | $0.03 | ($0.08) | - | ($0.15) | ($0.10) | ($0.10) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $204.36M | $232.67M | $219.40M | $212.00M | $373.03M | $370.06M | $358.89M | $349.54M | $444.63M | $523.02M |
| Accounts Receivable | $18.61M | $21.74M | $22.21M | $25.05M | $23.26M | $27.64M | $36.28M | $41.41M | $47.67M | $54.70M |
| Inventory | $47.69M | $48.01M | $56.15M | $59.19M | $65.63M | $69.11M | $73.44M | $77.14M | $95.72M | $91.32M |
| Accounts Payable | $15.88M | $15.63M | $17.29M | $22.98M | $23.14M | $21.94M | $23.08M | $26.69M | $37.31M | $44.77M |
| Current Assets | $277.69M | $309.52M | $308.37M | $306.11M | $469.37M | $477.12M | $485.05M | $489.63M | $614.82M | $698.25M |
| Total Assets | $473.23M | $499.80M | $503.64M | $507.56M | $673.82M | $685.68M | $699.55M | $711.83M | $844.74M | $929.11M |
| Current Liabilities | $155.20M | $186.28M | $61.90M | $59.44M | $62.80M | $68.15M | $73.95M | $75.43M | $93.57M | $115.01M |
| Long-term Debt | - | - | $363.39M | $552.20M | - | - | - | - | - | - |
| Total Liabilities | $417.99M | $438.75M | $437.98M | $433.56M | $627.76M | $633.88M | $639.82M | $642.64M | $781.45M | $869.72M |
| Stockholders' Equity | $55.24M | $61.06M | $65.66M | $74.00M | $46.06M | $51.80M | $59.72M | $69.19M | $63.30M | $59.39M |
| Retained Earnings | ($524.11M) | ($517.48M) | ($509.38M) | ($498.35M) | ($518.06M) | ($507.96M) | ($497.63M) | ($479.34M) | ($479.55M) | ($478.87M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($5.55M) | - | - | - | $3.00M | - | - | - | ($16.85M) | - |
| Investing Cash Flow | ($1.65M) | - | - | - | ($1.15M) | - | - | - | ($1.80M) | - |
| Financing Cash Flow | ($20.91M) | - | - | - | ($250.0K) | - | - | - | ($58.62M) | - |
| CapEx | $224.0K | - | - | - | $45.0K | - | - | - | $344.0K | - |
| Free Cash Flow | ($5.78M) | - | - | - | $2.95M | - | - | - | ($17.20M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 68.5% | - | 64.6% | 62.8% | 69.8% | - | 51.6% | 45.2% | 59.4% | - |
| Operating margin | -2.8% | - | -8.8% | -3.5% | -17.3% | - | -27.3% | -24.4% | -20.9% | - |
| EBITDA margin | -1.9% | - | - | - | -14.6% | - | - | - | -17.5% | - |
| Net margin | -10.2% | - | -15.6% | 25.2% | -14.5% | - | -23.2% | 0.2% | -0.8% | - |
| Free cash flow margin | -8.9% | - | - | - | 4.2% | - | - | - | -21.1% | - |
| FCF / Net income | 0.87 | - | - | - | -0.29 | - | - | - | 25.33 | - |
| R&D / Revenue | 1.7% | - | 2.4% | 1.6% | 1.4% | - | 1.4% | 1.3% | 3.4% | - |
| SG&A / Revenue | 33.8% | - | 41.4% | 35.1% | 48.2% | - | 42.4% | 34.7% | 35.5% | - |
| Effective tax rate | - | - | - | -5.3% | - | - | - | - | - | - |
| Return on assets | -1.4% | - | -2.2% | 3.9% | -1.5% | - | -2.6% | 0.0% | -0.1% | - |
| Return on equity | -12.0% | - | -16.8% | 26.6% | -21.9% | - | -30.6% | 0.3% | -1.1% | - |
| Return on invested capital | - | - | -1.1% | -0.4% | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.79 | 1.66 | 4.98 | 5.15 | 7.47 | 7.00 | 6.56 | 6.49 | 6.57 | 6.07 |
| Quick ratio | 1.48 | 1.40 | 4.07 | 4.15 | 6.43 | 5.99 | 5.57 | 5.47 | 5.55 | 5.28 |
| Cash ratio | 1.32 | 1.25 | 3.54 | 3.57 | 5.94 | 5.43 | 4.85 | 4.63 | 4.75 | 4.55 |
| Leverage | ||||||||||
| Debt / Equity | - | - | 5.53 | 7.46 | - | - | - | - | - | - |
| Debt / Assets | - | - | 0.72 | 1.09 | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -0.3x | - | -1.0x | -0.7x | -4.0x | - | -6.2x | -9.0x | -5.6x | - |
| Equity multiplier | 8.57 | 8.19 | 7.67 | 6.86 | 14.63 | 13.24 | 11.71 | 10.29 | 13.35 | 15.64 |
| Liabilities / Assets | 0.88 | 0.88 | 0.87 | 0.85 | 0.93 | 0.92 | 0.91 | 0.90 | 0.93 | 0.94 |
| Efficiency | ||||||||||
| Asset turnover | 0.14 | - | 0.14 | 0.15 | 0.10 | - | 0.11 | 0.13 | 0.10 | - |
| Inventory turnover | 0.43 | - | 0.45 | 0.49 | 0.32 | - | 0.52 | 0.64 | 0.35 | - |
| Days sales outstanding | 105d | - | 115d | 117d | 122d | - | 168d | 167d | 214d | - |
| Days inventory outstanding | 850d | - | 819d | 743d | 1141d | - | 703d | 567d | 1057d | - |
| Days payable outstanding | 283d | - | 252d | 288d | 402d | - | 221d | 196d | 412d | - |
| Cash conversion cycle | 672d | - | 681d | 572d | 861d | - | 650d | 538d | 859d | - |
| Valuation | ||||||||||
| P / E | - | - | - | 63.7x | - | - | - | - | - | - |
| P / B | 2.1x | - | 3.8x | 3.6x | 3.6x | - | 3.0x | 3.9x | 10.1x | - |
| P / S | 1.8x | - | 3.6x | 3.4x | 2.4x | - | 2.3x | 3.0x | 7.9x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -6.7% | - | -10.3% | -13.7% | -14.5% | - | -19.1% | -22.9% | -5.7% | - |
| Revenue CAGR (3y) | -9.0% | - | -7.3% | -8.9% | 13.5% | - | 31.6% | 10.9% | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | -8.5% | - | 12.3% | 20.0% | 0.5% | - | - | -39.7% | -10.6% | - |
| Operating income growth (YoY) | 85.0% | - | 71.0% | 87.8% | 29.2% | - | 73.8% | -68.2% | 1.8% | - |
| Net income growth (YoY) | 34.3% | - | 39.7% | 9658.4% | -1386.9% | - | 75.2% | -94.0% | 97.0% | - |
| EPS growth (YoY) | 37.5% | - | 40.0% | - | 20.0% | - | 73.2% | - | 41.2% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | -12.2% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 19.9% | 17.9% | 9.9% | 7.0% | -27.2% | -12.8% | -33.6% | -57.2% | -57.1% | -65.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$300.79M totalConsumables$212.71M · 70.7%
Delivery Systems$88.08M · 29.3%
Geographic
$300.79M totalAmericas$203.98M · 67.8%
EMEA$68.30M · 22.7%
Asia Pacific$28.52M · 9.5%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing Beauty Health Co against the 5 most active filers in the same SIC group.